keyword
MENU ▼
Read by QxMD icon Read
search

Adalimumab

keyword
https://www.readbyqxmd.com/read/28426849/effect-of-adalimumab-on-visual-functioning-in-patients-with-noninfectious-intermediate-uveitis-posterior-uveitis-and-panuveitis-in-the-visual-1-and-visual-2-trials
#1
John Sheppard, Avani Joshi, Keith A Betts, Stacie Hudgens, Samir Tari, Naijun Chen, Martha Skup, Andrew D Dick
Importance: Adalimumab was recently approved for the treatment of noninfectious intermediate uveitis, posterior uveitis, and panuveitis. Objective: To assess the effect of adalimumab on the visual functioning and quality of life in patients with corticosteroid-dependent noninfectious intermediate uveitis, posterior uveitis, and panuveitis. Design: A post hoc analysis of clinical trials of adults with active (VISUAL-1) and inactive (VISUAL-2) noninfectious intermediate uveitis, posterior uveitis, and panuveitis was conducted in the United States, Canada, Europe, Israel, Australia, Latin America, and Japan...
April 20, 2017: JAMA Ophthalmology
https://www.readbyqxmd.com/read/28426141/melanocortin-2-3-and-4-receptor-gene-expressions-are-downregulated-in-cd8-t-cytotoxic-lymphocytes-and-cd19-b-lymphocytes-in-rheumatoid-arthritis-responding-to-tnf%C3%AE-inhibition
#2
Marlene Andersen, Ivan Nagaev, Michael Kruse Meyer, Olga Nagaeva, Jarl Wikberg, Lucia Mincheva-Nilsson, Grethe Neumann Andersen
Melanocortin signaling in leukocyte subsets elicits anti-inflammatory and immune tolerance inducing effects in animal experimental inflammation. In man, however, the effects of melanocortin signaling in inflammatory conditions have scarcely been examined. We explored the differential reactions of melanocortin 1-5 receptor (MC1-5R) gene expressions in pathogenetic leukocyte subsets in rheumatoid arthritis (RA) to treatment with TNFα inhibitor adalimumab. Seven patients with active RA donated blood at start and at three months treatment...
April 20, 2017: Scandinavian Journal of Immunology
https://www.readbyqxmd.com/read/28425772/prediction-of-successful-dose-reduction-or-discontinuation-of-adalimumab-etanercept-or-infliximab-in-rheumatoid-arthritis-patients-using-serum-drug-levels-and-antidrug-antibody-measurement
#3
Cam Bouman, N van Herwaarden, Fhj van den Hoogen, A van der Maas, Bjf van den Bemt, A A den Broeder
BACKGROUND: To evaluate if TNF inhibitor serum drug levels (DL) or anti-drug antibodies (ADAb) can predict successful dose reduction (in patients with high DL) or discontinuation (in patients with no/low DL or ADAb) in rheumatoid arthritis (RA) patients. RESEARCH DESIGN AND METHODS: RA patients that were using adalimumab (n=42), etanercept (n=76) or infliximab (n=51) and were doing well, were tapered until discontinuation or flare (1-1.5 year follow up). Random timed DL for adalimumab and etanercept and trough DL for infliximab were measured before dose reduction: Receiver-Operator-Curves (ROC) analyses with optimal cut-off DL were determined...
April 20, 2017: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/28422861/does-long-term-efficacy-differ-between-infliximab-and-adalimumab-after-1-year-of-continuous-administration-a-strobe-compliant-retrospective-cohort-study
#4
Haruka Otake, Satohiro Matsumoto, Hirosato Mashima
Although biologics are important inflammatory bowel disease therapies, loss of response (LOR) remains problematic. We evaluated LOR to biologics in our Crohn disease (CD) patients receiving biologics. Of 137 biologic-treated CD patients, 68 continuously receiving the same biologic type for at least 1 year were divided into 2 groups: infliximab (IFX) (n = 39) and adalimumab (ADA) (n = 29). Clinical courses were compared at biologic introduction and at 1 year. Both groups were retrospectively analyzed for LOR at and beyond 1 year after biologic introduction (study endpoint)...
April 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28421991/patterns-in-use-and-costs-of-conventional-and-biologic-disease-modifying-anti-rheumatic-drugs-in-australia
#5
Ellen Donges, Christine Staatz, Helen Benham, Paul Kubler, Samantha A Hollingworth
OBJECTIVES: The aim of this study was to characterise the use and costs of subsidising conventional disease-modifying anti-rheumatic drugs (DMARDs) and biologic DMARDs in Australia from 2004-2014 through pharmaceutical benefits schemes. METHODS: Dispensing and expenditure data on conventional and biologic DMARDs were extracted from Medicare Australia and temporal trends were analysed. Medicine use was standardised in terms of the defined daily dose (DDD) per 1,000 population per day (DDD/1,000 population/day)...
April 18, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28421729/effects-of-tnf-%C3%AE-inhibitors-in-patients-with-psoriasis-and-metabolic-syndrome-a-preliminary-study
#6
Giulia Merlo, Emanuele Cozzani, Martina Burlando, Stefano Calvieri, Concetta Potenza, Luca Stingeni, Giorgio Filosa, Monica Pau, Marco Simonacci, Marzia Caproni, Aurora Parodi
BACKGROUND: Psoriasis is an inflammatory disease, that is increasingly being considered as a systemic disorder. Among associated comorbidities, metabolic syndrome plays an important role. The effects of biological therapies on metabolic syndrome is controversial. METHODS: Thirty-one psoriatic patients with metabolic syndrome, eligible to treatment with anti-TNFα agents, were enrolled. Metabolic parameters were measured during 4 subsequent visits, one every 40 to 60 days...
April 19, 2017: Giornale Italiano di Dermatologia e Venereologia: Organo Ufficiale, Società Italiana di Dermatologia e Sifilografia
https://www.readbyqxmd.com/read/28418334/juvenile-idiopathic-arthritis
#7
Kenan Barut, Amra Adrovic, Sezgin Şahin, Özgür Kasapçopur
Juvenile idiopathic arthritis is the most common chronic rheumatic disease of unknown aetiology in childhood and predominantly presents with peripheral arthritis. The disease is divided into several subgroups, according to demographic characteristics, clinical features, treatment modalities and disease prognosis. Systemic juvenile idiopathic arthritis, which is one of the most frequent disease subtypes, is characterized by recurrent fever and rash. Oligoarticular juvenile idiopathic arthritis, common among young female patients, is usually accompanied by anti-nuclear antibodie positivity and anterior uveitis...
April 5, 2017: Balkan Medical Journal
https://www.readbyqxmd.com/read/28417141/incidence-and-prevalence-of-psoriasis-in-denmark
#8
Alexander Egeberg, Lone Skov, Gunnar H Gislason, Jacob P Thyssen, Lotus Mallbris
The incidence and temporal trends of psoriasis in Denmark between 2003 and 2012 were examined. There was a female predominance ranging between 50.0% (2007) and 55.4% (2009), and the mean age at time of diagnosis was 47.7-58.7 years. A total of 126,055 patients with psoriasis (prevalence 2.2%) were identified. Incidence rates of psoriasis (per 100,000 person years) ranged from 107.5 in 2005 to a peak incidence of 199.5 in 2010. Incidence rates were higher for women, and patients aged 60-69 years, respectively...
April 18, 2017: Acta Dermato-venereologica
https://www.readbyqxmd.com/read/28416240/efficacy-of-tumour-necrosis-factor-antagonists-in-stricturing-crohn-s-disease-a-tertiary-center-real-life-experience
#9
Mariangela Allocca, Cristiana Bonifacio, Gionata Fiorino, Antonino Spinelli, Federica Furfaro, Luca Balzarini, Stefanos Bonovas, Silvio Danese
BACKGROUND: Stenosis is the most common complication of Crohn's disease (CD). Long-term outcome of patients receiving tumour necrosis factor (TNF) antagonists for such disease complication is poorly understood. METHODS: 51 CD patients (from July 2006 to November 2015) who had a diagnosis of small bowel or colonic stenosis, diagnosed by colonoscopy and/or MRI enterography, and were treated with TNF antagonists (adalimumab or infliximab) were enrolled. The primary outcome was to assess the rate of success of TNF antagonists on avoiding abdominal surgery for stricturing CD patients...
March 30, 2017: Digestive and Liver Disease
https://www.readbyqxmd.com/read/28414674/a-clot-possibly-due-to-loss-of-tnf-%C3%AE-supression
#10
J Broussard, M Berlinger, D Lauret
INTRODUCTION: Inflammation and venous thrombosis enjoy a close Relationship. We present a patient who had multiple DVTs following the discontinuation of anti- TNF-α therapy. CASE: A 34 year old African American female with a history of multiple DVT's, miscarriages, and reported Crohn's disease presented with shortness of breath. In the Emergency Department, CTA showed bilateral pulmonary emboli. The patient had been off adalimumab for one year and reported abdominal pain with 6-7 non-bloody bowel movements daily...
March 2017: Journal of the Louisiana State Medical Society: Official Organ of the Louisiana State Medical Society
https://www.readbyqxmd.com/read/28413099/second-line-biologic-therapy-optimization-in-rheumatoid-arthritis-psoriatic-arthritis-and-ankylosing-spondylitis
#11
REVIEW
Fabrizio Cantini, Laura Niccoli, Carlotta Nannini, Emanuele Cassarà, Olga Kaloudi, Ennio Giulio Favalli, Andrea Becciolini, Maurizio Benucci, Francesca Li Gobbi, Serena Guiducci, Rosario Foti, Marta Mosca, Delia Goletti
OBJECTIVE: The Italian board for the TAilored BIOlogic therapy (ITABIO) reviewed the most consistent literature to indicate the best strategy for the second-line biologic choice in patients with rheumatoid arthritis (RA), spondyloarthritis (SpA), and psoriatic arthritis (PsA). METHODS: Systematic review of the literature to identify English-language articles on efficacy of second-line biologic choice in RA, PsA, and ankylosing spondylitis (AS). Data were extracted from available randomized, controlled trials, national biologic registries, national healthcare databases, post-marketing surveys, and open-label observational studies...
March 22, 2017: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/28411169/the-impact-of-immunogenicity-of-tnf%C3%AE-inhibitors-in-autoimmune-inflammatory-disease-a-systematic-review-and-meta-analysis
#12
REVIEW
Valentina Pecoraro, Elena De Santis, Alessandra Melegari, Tommaso Trenti
BACKGROUND: Monoclonal antibodies drugs directed against TNFα, TNFα inhibitors, are immunogenic, and consequent anti-drug antibodies (ADA) formation may decrease the functional drug concentration, resulting in a loss of response. We evaluated the impact of ADA on TNFα therapeutic response. METHODS: We considered studies enrolling adult patients affected by autoimmune inflammatory disease in therapy with TNFα inhibitors. We collected data about study and population characteristics, treatment dosage, determination of ADA and adverse events (AE)...
April 11, 2017: Autoimmunity Reviews
https://www.readbyqxmd.com/read/28410817/medication-adherence-and-persistence-over-time-with-self-administered-tnf-alpha-inhibitors-among-young-adult-middle-aged-and-older-patients-with-rheumatologic-conditions
#13
Gregory S Calip, Sruthi Adimadhyam, Shan Xing, Julian C Rincon, Wan-Ju Lee, Rebekah H Anguiano
OBJECTIVE: Self-injectable TNF inhibitors are increasingly used early in the chronic treatment of moderate to severe rheumatologic conditions. We estimated medication adherence/persistence over time following initiation in young adult and older adult patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis. METHODS: We conducted a retrospective cohort study of patients aged 18+ years newly initiating etanercept, adalimumab, certolizumab pegol, or golimumab using the Truven Health MarketScan Database between 2009 and 2013...
March 21, 2017: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/28407999/cost-effectiveness-of-tnf-blocker-injection-spacing-for-patients-with-established-rheumatoid-arthritis-in-remission-an-economic-evaluation-from-the-spacing-of-tnf-blocker-injections-in-rheumatoid-arthritis-trial
#14
Antoine Vanier, Xavier Mariette, Florence Tubach, Bruno Fautrel
BACKGROUND: In patients with rheumatoid arthritis in remission, a disease activity-driven tapering of adalimumab or etanercept relying on progressive injection spacing has not been shown to be equivalent to a maintenance strategy at full dose in terms of disease activity in the Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study (STRASS) trial. OBJECTIVES: To evaluate the cost-effectiveness of such a spacing strategy based on the data of the STRASS trial...
April 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28406587/reversible-corpus-callosal-lesions-associated-with-the-use-of-adalimumab-for-ulcerative-colitis
#15
Jin Woo Park, Hung Yuol Seok, Yoohwan Kim, Byung Jo Kim
No abstract text is available yet for this article.
April 2017: Journal of Clinical Neurology
https://www.readbyqxmd.com/read/28405767/erratum-to-four-year-maintenance-treatment-with-adalimumab-in-japanese-patients-with-moderately-to-severely-active-ulcerative-colitis
#16
Yasuo Suzuki, Satoshi Motoya, Hiroyuki Hanai, Toshifumi Hibi, Shiro Nakamura, Andreas Lazar, Anne Martin Robinson, Martha Skup, Nael Mohamed Mostafa, Bidan Huang, Roopal Thakkar, Mamoru Watanabe
No abstract text is available yet for this article.
April 12, 2017: Journal of Gastroenterology
https://www.readbyqxmd.com/read/28402696/chronic-cough-and-an-atypical-peripheral-pattern-on-chest-imaging-a-case-report-secondary-to-suspected-drug-onset
#17
Ronnie Alas, Mark Tony Williams, Ghiam Yamin, Mohsen Rofoogaran
INTRODUCTION: Chronic eosinophilic pneumonia (CEP) is an uncommon interstitial lung disease with nonspecific symptoms that is a diagnostic and treatment challenge. The exact pathology is unknown and putatively involves a complex inflammatory cascade associated with the abnormal accumulation of eosinophils. Our patient had a history of adult-onset asthma after initiating TNF-inhibitor therapy. CEP coexisting with asthma has been reported, but never linked to the use of a TNF-inhibitor-as we report here...
April 12, 2017: Journal of Asthma: Official Journal of the Association for the Care of Asthma
https://www.readbyqxmd.com/read/28402454/adalimumab-vs-azathioprine-in-the-prevention-of-postoperative-crohn-s-disease-recurrence-a-geteccu-randomized-trial
#18
Antonio López-Sanromán, Isabel Vera-Mendoza, Eugeni Domènech, Carlos Taxonera, Vicente Vega Ruiz, Ignacio Marín-Jiménez, Jordi Guardiola, Luisa Castro, María Esteve, Eva Iglesias, Daniel Ceballos, Pilar Martínez-Montiel, Javier P Gisbert, Miguel Mínguez, Ana Echarri, Xavier Calvet, Jesús Barrio, Joaquín Hinojosa, María Dolores Martín-Arranz, Lucía Márquez-Mosquera, Fernando Bermejo, Jordi Rimola, Vicente Pons, Pilar Nos
Background and Aims: Postoperative recurrence of Crohn's disease (POR-CD) is almost certain if no prophylaxis is administered. Evidence for optimal treatment is lacking. Our aim was to compare the efficacy of adalimumab (ADA) and azathioprine (AZA) in this setting. Methods: We performed a phase 3, 52-week, multicenter, randomized, superiority study (APPRECIA), in which patients with ileocolic resection were randomized either to ADA 160-80-40 mg SC or AZA 2.5 mg/kg/d, both associated to metronidazole...
April 11, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28400083/proposal-for-an-anti-tnf-exit-strategy-based-on-trough-serum-level
#19
Ulf Helwig, Frederik Lutter, Nadine Koppka, Stefan Schreiber
BACKGROUND AND AIMS: The aim of the study was to evaluate, if the strategy to stop anti-TNF treatment after determination of low trough serum levels and exclusion of inflammation is associated with lower relapse rates. METHODS: Since 2013 we followed an exit strategy in patients treated with anti-TNF treatment for inflammatory bowel disease based on trough serum levels. The relapse rates were observed prospectively, data analysis was performed in a retrospective manner of the collected clinical data...
April 8, 2017: Biologicals: Journal of the International Association of Biological Standardization
https://www.readbyqxmd.com/read/28392668/treatment-of-recalcitrant-pyoderma-gangrenosum-with-ulcerative-colitis-by-adalimumab-injection
#20
Jin-Hyup Lee, In-Kyu Chang, Hae-Eul Lee, Myung Im, Young-Joon Seo, Jeung-Hoon Lee, Young Lee
No abstract text is available yet for this article.
April 2017: Annals of Dermatology
keyword
keyword
1884
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"